Although originally developed as chemosensitisers, these compounds induce synthetic lethality in tumour cells from patients carrying germline loss-of-function mutations in DNA damage pathway tumour suppressor genes BRCA1 and BRCA2 (Lord & Ashworth 2012). This evidence concerns the gene BRCA1 and neoplasm.